Alterity Therapeutics (ATHE) has released an update.
Alterity Therapeutics has reported a successful quarter, with promising Phase 2 trial results for their neurodegenerative disease treatment, ATH434, and a strong cash balance of A$18.3M after raising A$5.25M and receiving an A$3.9M tax refund. The company remains on track to report further trial data in the coming year and continues to advance its understanding of Multiple System Atrophy through its bioMUSE study.
For further insights into ATHE stock, check out TipRanks’ Stock Analysis page.
